HD
31
-3
MTB
49
-14
NWL
37
-2
VLO
40
-2
CLX
48
-2
HIG
70
2
ILMN
37
-3
SCHW
37
-2
TRIP
55
3
TSCO
51
-2
HAS
43
-2
MA
43
2
SWK
45
-4
M
23
-5
WBA
19
-3
PH
69
2
PFE
30
5
KEY
29
-4
CMS
57
4
FTI
61
-2
HD
31
-3
MTB
49
-14
NWL
37
-2
VLO
40
-2
CLX
48
-2
HIG
70
2
ILMN
37
-3
SCHW
37
-2
TRIP
55
3
TSCO
51
-2
HAS
43
-2
MA
43
2
SWK
45
-4
M
23
-5
WBA
19
-3
PH
69
2
PFE
30
5
KEY
29
-4
CMS
57
4
FTI
61
-2
Financhill
Back

Stoke Therapeutics 10K Form

Sell
35

STOK
Stoke Therapeutics

Last Price:
11.75
Seasonality Move:
-0.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STOK News And Ratings

See the #1 stock for the next 7 days that we like better than STOK

STOK Financial Statistics

Sales & Book Value

Annual Sales: $12.41M
Cash Flow: $-21.52M
Price / Cash Flow: 0
Annual Sales: $4.84
Price / Book: 2.43

Profitability

EPS (TTM): -2.47000
Net Income (TTM): $-98.96M
Gross Margin: --
Return on Equity: -46.37%
Return on Assets: -34.53%

Stoke Therapeutics Earnings Forecast

Key Stoke Therapeutics Financial Ratios

  • The Research & Development expenses have been 627.24% of Revenue.
  • The Net Earning history of STOK is -814.42% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Stoke Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: STOK
CUSIP: 86150R
Website: stoketherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.57
Quick Ratio: 8.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STOK Technical Analysis vs Fundamental Analysis

Sell
35
Stoke Therapeutics (STOK) is a Sell

Is Stoke Therapeutics a Buy or a Sell?